|Bid||84.71 x 100|
|Ask||87.44 x 100|
|Day's Range||85.27 - 86.14|
|52 Week Range||74.00 - 89.09|
|PE Ratio (TTM)||40.85|
|Forward Dividend & Yield||2.25 (2.61%)|
|1y Target Est||N/A|
A U.S. Senate committee on Wednesday voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar's nomination, with all but one Democrat opposing. To receive final confirmation Azar will have to receive a majority vote in the 100-seat Senate, which Republicans control with 51 seats.
A key Senate committee on Wednesday voted to advance the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar's nomination with all but one Democrat opposing. To receive final confirmation Azar will have to receive a majority vote in the 100-seat Senate, which Republicans control with 51 seats.
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.
Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.
The case for buying shares of Eli Lilly and Co (NYSE: LLY ) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes ...
Big pharmaceutical stocks are moving in disparate directions on Tuesday, with Merck (MRK) rising on good news while Eli Lilly (LLY) was falling after a downgrade. Merck is higher after late-stage trial data showed that Keytruda, when used with two chemotherapy drugs, was successful as a first-line treatment for lung cancer. While the blockbuster drug is already approved for use for cancer treatment, including lung cancer, the results were good news, as Merck and other Big Pharma companies are racing to bring new lung-cancer treatment options to market. As for Eli Lilly, Goldman Sachs' Jami Rubin and her team downgraded the stock from Buy to Neutral, writing that while they are still bullish on the company's long term, they're concerned that the bull thesis is well understood and already reflected in the stock's valuation. Moreover, Rubin argues, the risk to Lilly's diabetes franchise, particularly Trulicity--the company's biggest and fastest growth driver--isn't fully appreciated by the market, and that could cause downside to consensus estimates.
Outcomes on these three clinical trials in diabetes this year could change the way the disease is treated going into the next decade.
Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.
What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.
Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, indicated on Tuesday he supported a Republican bid to overhaul Medicaid and again vowed to tackle high drug prices. Azar appeared before the Senate Finance Committee on Tuesday, which will ultimately decide whether to move his nomination forward. Azar also vowed to uphold Obamacare as long as it remained the law but said that the program needed changes.
WASHINGTON (AP) — Empowering Medicare to negotiate drug prices could leave patients with reduced access to medications, President Donald Trump's pick for health secretary warned Tuesday.
As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.
AbbVie (ABBV) is focused on expanding Risankizumab’s label for multiple indications such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease. The company expects to witness a significant rise in demand for Crohn’s disease and ulcerative colitis patients, mainly driven by increasing diagnosis rates and the greater prevalence of patients already treated with biologics.
Efforts to find treatments for Alzheimer’s disease suffered blows in recent days, but many companies, scientists and investors are still optimistic that they can find a way to treat the memory-robbing ...
Eli Lilly & Co. Chief Executive Officer Dave Ricks said on Monday that the recent changes in U.S. tax policy will help the drugmaker lower its global tax burden as he continues to look for deals in areas ...
Jan.09 -- David Ricks, chairman and chief executive officer at Eli Lilly & Co., discusses pricing pressures, the drug Trulicity, and the company's commitment to diabetes research. He speaks with Erik Schatzker on "Bloomberg Markets" from the JPMorgan Health Care conference in San Francisco.
Jan.09 -- David Ricks, chairman and chief executive officer at Eli Lilly & Co., discusses drug pricing and shifting industry dynamics. He speaks with Erik Schatzker on "Bloomberg Markets" from the JPMorgan Healthcare Conference in San Francisco.